前列腺癌在多参数磁共振成像上可见性的分子相关性:一项系统综述
该系统综述检索了截至2023年11月的PubMed、Scopus和Web of Science数据库,从2015条记录中筛选25条进行定性综合,比较MRI可见与不可见前列腺癌病灶的基因组、转录组和蛋白质组特征。现有证据支持MRI可见性是多基因性状,主要受基质、黏附和细胞组织相关基因影响;高PI-RADS评分与生物学和临床侵袭性前列腺癌分子表型相关,可能作为生物标志物,但MRI不可见病灶也可具有不良特征,支持继续使用系统活检。
要点
- MRI可见性是多基因性状,主要受基质、黏附和细胞组织相关基因影响。
- 高PI-RADS评分与生物学和临床侵袭性前列腺癌分子表型相关,可能作为生物标志物。
- MRI不可见病灶也可具有侵袭性前列腺癌的分子特征,支持继续使用系统活检。
核心结论
- 高PI-RADS评分与生物学和临床侵袭性前列腺癌分子表型相关,可能作为生物标志物。
- MRI不可见病灶可具有不良特征,支持继续使用系统活检。
- 需要进一步研究以完善影像数据与预后评估的整合。
研究设计与样本
- 系统综述,检索PubMed、Scopus和Web of Science数据库截至2023年11月。
- 从2015条记录中筛选25条进行定性数据综合。
- 根据PI-RADS评分定义MRI可见和MRI不可见病灶,比较其基因组、转录组和蛋白质组特征。
主要发现
- 当前证据支持MRI可见性是多基因性状,主要受基质、黏附和细胞组织相关基因影响。
- 多个与MRI可见性相关的基因特征与肿瘤学结局相关,支持表现为PI-RADS 4-5病灶的肿瘤携带致死性疾病。
- 通过系统活检检测的MRI不可见肿瘤通常侵袭性较低且预后更有利,但一些MRI不可见肿瘤具有生物学侵袭性前列腺癌的分子特征。
- 在商业可用的预后基因panel中,仅Decipher与MRI可见性强相关。
关键数值与推荐
- 根据PI-RADS评分定义MRI可见和MRI不可见病灶。
- 在商业可用的预后基因panel中,仅Decipher与MRI可见性强相关。
临床怎么用
- 高PI-RADS评分与生物学和临床侵袭性前列腺癌分子表型相关,可能作为生物标志物。
- MRI不可见病灶可具有不良特征,支持继续使用系统活检。
- 需要进一步研究以完善影像数据与预后评估的整合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Although prostate magnetic resonance imaging (MRI) is increasingly used to diagnose and stage prostate cancer (PCa), the biologic and clinical significance of MRI visibility of the disease is unclear. Our aim was to examine the existing knowledge regarding the molecular correlates of MRI visibility of PCa. METHODS: The PubMed, Scopus, and Web of Science databases were queried through November 2023. We defined MRI-visible and MRI-invisible lesions based on the Prostate Imaging Reporting and Data System (PI-RADS) score, and compared these based on the genomic, transcriptomic, and proteomic characteristics. KEY FINDINGS AND LIMITATIONS: From 2015 individual records, 25 were selected for qualitative data synthesis. Current evidence supports the polygenic nature of MRI visibility, primarily influenced by genes related to stroma, adhesion, and cellular organization. Several gene signatures related to MRI visibility were associated with oncologic outcomes, which support that tumors appearing as PI-RADS 4-5 lesions harbor lethal disease. Accordingly, MRI-invisible tumors detected by systematic biopsies were, generally, less aggressive and had a more favorable prognosis; however, some MRI-invisible tumors harbored molecular features of biologically aggressive PCa. Among the commercially available prognostic gene panels, only Decipher was strongly associated with MRI visibility. CONCLUSIONS AND CLINICAL IMPLICATIONS: High PI-RADS score is associated with biologically and clinically aggressive PCa molecular phenotypes, and could potentially be used as a biomarker. However, MRI-invisible lesions can harbor adverse features, advocating the continued use of systemic biopsies. Further research to refine the integration of imaging data to prognostic assessment is warranted. PATIENT SUMMARY: Magnetic resonance imaging visibility of prostate cancer is a polygenic trait. Higher Prostate Imaging Reporting and Data System scores are associated with features of biologically and clinically aggressive cancer.
引用
- Fazekas T, Pallauf M, Kufel J, et al. Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. Eur Urol Oncol. 2024. PMID: 39414421. doi:10.1016/j.euo.2024.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。